IL17A and neoplasm: Moreover, in the mouse model of OSCC, it has been shown that inhibition of IL-17A combined with the PD-1 blockade delayed the development of precancerous and cancerous lesions and prolonged the survival of 4NQO-treated mice, suggesting the IL-17A blockade as a potential approach to augment the tumor eliminating effects of anti-PD-1 therapy [92].